JOP20200137A1 - نظائر إنكريتين واستخداماتها - Google Patents
نظائر إنكريتين واستخداماتهاInfo
- Publication number
- JOP20200137A1 JOP20200137A1 JOP/2020/0137A JOP20200137A JOP20200137A1 JO P20200137 A1 JOP20200137 A1 JO P20200137A1 JO P20200137 A JOP20200137 A JO P20200137A JO P20200137 A1 JOP20200137 A1 JO P20200137A1
- Authority
- JO
- Jordan
- Prior art keywords
- incretin analogs
- activity
- receptors
- incretin
- analogs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Details Of Garments (AREA)
Abstract
يتعلق الاختراع الحالي بنظائر الإنكريتين التي لها نشاط عند كل من مستقبلات GIP، GLP-1 والجلوكاجون. تمتلك نظائر الإنكريتين ميزات بنائية تؤدي إلى الحصول على نشاط متوازن ومفعول طويل المدى عند كل من هذه المستقبلات. ويتم أيضًا تقديم طرق لعلاج أمراض مثل مرض السكري، اختلال الدهون في الدم، مرض الكبد الدهني، متلازمة التمثيل الغذائي، التهاب الكبد الدهني غير الكحولي والسِّمنة.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762608613P | 2017-12-21 | 2017-12-21 | |
PCT/US2018/065663 WO2019125938A1 (en) | 2017-12-21 | 2018-12-14 | Incretin analogs and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20200137A1 true JOP20200137A1 (ar) | 2022-10-30 |
Family
ID=65003519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2020/0137A JOP20200137A1 (ar) | 2017-12-21 | 2018-12-14 | نظائر إنكريتين واستخداماتها |
Country Status (25)
Country | Link |
---|---|
US (2) | US11542313B2 (ar) |
EP (1) | EP3727426A1 (ar) |
JP (2) | JP6961838B2 (ar) |
KR (2) | KR102444783B1 (ar) |
CN (1) | CN111491658B (ar) |
AR (1) | AR113486A1 (ar) |
AU (1) | AU2018388962B2 (ar) |
BR (1) | BR112020010244A2 (ar) |
CA (1) | CA3084005C (ar) |
CL (1) | CL2020001635A1 (ar) |
CO (1) | CO2020006255A2 (ar) |
CR (1) | CR20200255A (ar) |
DO (1) | DOP2020000123A (ar) |
EA (1) | EA202091290A1 (ar) |
EC (1) | ECSP20032650A (ar) |
IL (1) | IL275468A (ar) |
JO (1) | JOP20200137A1 (ar) |
MA (1) | MA51288A (ar) |
MX (2) | MX2020006548A (ar) |
NZ (1) | NZ765277A (ar) |
PE (1) | PE20210162A1 (ar) |
PH (1) | PH12020551025A1 (ar) |
SG (1) | SG11202005606VA (ar) |
TW (3) | TWI744579B (ar) |
WO (1) | WO2019125938A1 (ar) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR113486A1 (es) * | 2017-12-21 | 2020-05-06 | Lilly Co Eli | Análogos de incretina y sus usos |
KR20210091230A (ko) * | 2018-11-12 | 2021-07-21 | 톈진 인스티튜트 오브 파마슈티컬 리서치 씨오., 엘티디. | 글루카곤 유도 펩티드 및 이의 용도 |
MX2022002115A (es) | 2019-08-19 | 2022-03-17 | Lilly Co Eli | Metodos para preparar analogos de incretina. |
TWI795698B (zh) * | 2019-12-18 | 2023-03-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
AR121650A1 (es) * | 2020-03-25 | 2022-06-22 | Takeda Pharmaceuticals Co | Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos |
WO2022090447A1 (en) | 2020-10-30 | 2022-05-05 | Novo Nordisk A/S | Glp-1, gip and glucagon receptor triple agonists |
CN114685642B (zh) * | 2020-12-29 | 2024-03-29 | 浙江和泽医药科技股份有限公司 | 一种肠促胰岛素类似物药学上可接受盐及制备方法和用途 |
KR102691149B1 (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
TWI837615B (zh) | 2021-03-23 | 2024-04-01 | 美商美國禮來大藥廠 | 含腸促胰島素(incretin)類似物之組合物及其用途 |
AU2022280225A1 (en) | 2021-05-26 | 2024-01-04 | The United Bio-Technology (Hengqin) Co., Ltd. | Multi-agonist and use thereof |
WO2022268029A1 (zh) * | 2021-06-21 | 2022-12-29 | 广东东阳光药业有限公司 | Glp-1、gcg和gip受体的三重激动剂 |
CN117915939A (zh) | 2021-06-23 | 2024-04-19 | 伊莱利利公司 | 肠降血糖素类似物用于血糖控制和体重管理 |
EP4434536A1 (en) * | 2021-11-19 | 2024-09-25 | Medshine Discovery Inc. | Stapled peptide and use thereof |
TWI828434B (zh) * | 2021-11-19 | 2024-01-01 | 大陸商南京明德新藥研發有限公司 | 釘合肽及其應用 |
CN116162147B (zh) * | 2021-11-24 | 2023-10-03 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
CN114957387B (zh) * | 2022-05-18 | 2023-06-20 | 华南理工大学 | 一种具有降血糖作用的巴旦木多肽及其制备方法与应用 |
WO2024050289A1 (en) | 2022-08-29 | 2024-03-07 | Eli Lilly And Company | Compositions for oral delivery |
CN117417411A (zh) * | 2022-09-28 | 2024-01-19 | 广东东阳光药业股份有限公司 | Glp-1/gcg/gip三受体激动剂及其用途 |
WO2024077149A2 (en) | 2022-10-05 | 2024-04-11 | Eli Lilly And Company | Peptides for incretin synthesis |
WO2024141760A1 (en) | 2022-12-30 | 2024-07-04 | Algipharma As | Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration |
US20240270821A1 (en) | 2023-01-31 | 2024-08-15 | Eli Lilly And Company | Gip/glp1/gcg tri-receptor agonists and uses thereof |
WO2024213022A1 (zh) * | 2023-04-11 | 2024-10-17 | 上海多米瑞生物技术有限公司 | 肠促胰素类似物及其制备方法和应用 |
CN117024528B (zh) * | 2023-07-07 | 2024-03-22 | 杭州信海医药科技有限公司 | 一种Retatrutide的制备方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010013453A (es) * | 2008-06-17 | 2011-01-21 | Univ Indiana Res & Tech Corp | Agonistas mezclados basados en gip para el tratamiento de desordenes metabolicos y obesidad. |
KR20110137819A (ko) | 2009-03-27 | 2011-12-23 | 글락소 그룹 리미티드 | 약물 융합체 및 컨쥬게이트 |
BR112012018104A2 (pt) * | 2010-01-20 | 2017-10-17 | Zeland Pharma As | tratamento de doenças cardíacas |
AR080592A1 (es) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
EP2707713A2 (en) * | 2011-05-10 | 2014-03-19 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
EA035688B1 (ru) * | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
TWI670281B (zh) * | 2013-11-06 | 2019-09-01 | 西蘭製藥公司 | Gip-glp-1雙重促效劑化合物及方法 |
JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
TWI669309B (zh) * | 2015-06-22 | 2019-08-21 | 美商美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
TWI622596B (zh) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
SG11201805573RA (en) | 2015-12-31 | 2018-07-30 | Hanmi Pharmaceutical Co Ltd | Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist |
EP3217027A1 (de) | 2016-03-08 | 2017-09-13 | HILTI Aktiengesellschaft | Breites einlageelement zum einfassen einer ankerstange |
TWI810937B (zh) * | 2017-12-21 | 2023-08-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
AR113486A1 (es) * | 2017-12-21 | 2020-05-06 | Lilly Co Eli | Análogos de incretina y sus usos |
-
2018
- 2018-12-05 AR ARP180103560A patent/AR113486A1/es unknown
- 2018-12-05 TW TW107143624A patent/TWI744579B/zh active
- 2018-12-05 TW TW110136047A patent/TWI809515B/zh active
- 2018-12-05 TW TW112124080A patent/TW202415675A/zh unknown
- 2018-12-14 AU AU2018388962A patent/AU2018388962B2/en active Active
- 2018-12-14 EP EP18830618.7A patent/EP3727426A1/en active Pending
- 2018-12-14 KR KR1020207017387A patent/KR102444783B1/ko active IP Right Grant
- 2018-12-14 JP JP2020551786A patent/JP6961838B2/ja active Active
- 2018-12-14 CN CN201880081212.3A patent/CN111491658B/zh active Active
- 2018-12-14 MX MX2020006548A patent/MX2020006548A/es unknown
- 2018-12-14 KR KR1020227031761A patent/KR102622642B1/ko active IP Right Grant
- 2018-12-14 CA CA3084005A patent/CA3084005C/en active Active
- 2018-12-14 SG SG11202005606VA patent/SG11202005606VA/en unknown
- 2018-12-14 JO JOP/2020/0137A patent/JOP20200137A1/ar unknown
- 2018-12-14 NZ NZ765277A patent/NZ765277A/en unknown
- 2018-12-14 CR CR20200255A patent/CR20200255A/es unknown
- 2018-12-14 BR BR112020010244-0A patent/BR112020010244A2/pt unknown
- 2018-12-14 US US16/768,960 patent/US11542313B2/en active Active
- 2018-12-14 MA MA051288A patent/MA51288A/fr unknown
- 2018-12-14 EA EA202091290A patent/EA202091290A1/ru unknown
- 2018-12-14 PE PE2020000802A patent/PE20210162A1/es unknown
- 2018-12-14 WO PCT/US2018/065663 patent/WO2019125938A1/en active Application Filing
-
2020
- 2020-05-22 CO CONC2020/0006255A patent/CO2020006255A2/es unknown
- 2020-06-17 CL CL2020001635A patent/CL2020001635A1/es unknown
- 2020-06-17 PH PH12020551025A patent/PH12020551025A1/en unknown
- 2020-06-17 IL IL275468A patent/IL275468A/en unknown
- 2020-06-17 DO DO2020000123A patent/DOP2020000123A/es unknown
- 2020-06-19 EC ECSENADI202032650A patent/ECSP20032650A/es unknown
- 2020-07-13 MX MX2024010201A patent/MX2024010201A/es unknown
-
2021
- 2021-10-13 JP JP2021168050A patent/JP2022033724A/ja active Pending
-
2022
- 2022-11-21 US US18/057,398 patent/US20230203121A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2024010201A (es) | Analogos de incretina y sus usos. | |
PH12020551024A1 (en) | Incretin analogs and uses thereof | |
PH12019501216A1 (en) | New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists | |
GEP20217265B (en) | Glp-1 receptor agonists and uses thereof | |
TN2017000148A1 (en) | Co-agonists of the glucagon and glp-1 receptors | |
MX2016004907A (es) | Analogos del glucagon. | |
PH12016500675A1 (en) | Acylated glucagon analogues | |
PH12015500531A1 (en) | Glucagon analogues | |
MX2016013243A (es) | Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4. | |
CR11849A (es) | Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad | |
MX2017012864A (es) | Analogo acilado del glucagon. | |
CR20220279A (es) | Análogos de incretina y sus usos | |
MX2019006427A (es) | Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip. |